NIPT First Test Light (aneuploidies of chromosomes 13, 18, 21)

Description

The First Test Light prenatal test is designed to determine the quantitative representation of the loci of the chromosomes under study in order to calculate the risk of fetal aneuploidies for chromosomes 21 (Down syndrome), 18 (Edwards syndrome), and 13 (Patau syndrome). This method is performed by direct analysis of cell-free fetal DNA in the pregnant woman's blood. The analysis of the data also takes into account the mother's age and gestational age. The test examines embryonic-placental extracellular DNA isolated from maternal plasma from 10 weeks of gestation. The risk of a genetic disorder in the child is assessed. The study makes it possible to suspect certain disorders and syndromes and then, with knowledge of them, carry out timely treatment of the child after birth. It should be taken into account that this is a screening test, meaning a diagnosis cannot be made based on its results. It assesses the probability of chromosomal abnormalities but does not allow for their definitive diagnosis even if a high risk is detected. The result of this test is not a diagnosis, but only a statistical probability figure. The test is performed starting from the 10th week of pregnancy. The method is suitable for both singleton and twin pregnancies. Prenatal genetic testing assesses the risk of chromosomal abnormalities. If there is a risk of disorders, one can be prepared for the diagnosis and take care in advance to ensure specialized support and medical care for the child. With current medical capabilities, a sufficiently high quality of life is possible for many congenital pathologies. Detection of an increased risk of developmental defects in the child is not a diagnosis. False-positive results are possible. The study is not performed in the following cases: - gestational age of less than 10 obstetric weeks at the time of blood collection; - oncological diseases; - organ or bone marrow transplantation, stem cell therapy; - allogeneic blood transfusion within one year; - therapy with human serum albumin and/or exogenous DNA cells within four weeks; - heparin therapy within 24 hours; - death of one of the fetuses in a multiple pregnancy (less than 8 weeks after the detection of the fetal demise); - pregnancy with more than two fetuses; - pregnancy with two fetuses using donor programs (donor egg, surrogacy).